What is the problem with semaglutide sodium or semaglutide acetate?

FDA has stated that these salt forms are not the same active ingredient as the semaglutide in the approved products and has raised concerns about compounders using them. A provider that names its pharmacy and confirms the base form answers this question; one that does not is recorded as not disclosing the formulation.

Published August 27, 2026 · updated August 27, 2026 · regulatory and clinical facts last checked 2026-08-27 · medically reviewed by Dr. S. Shuwart, MD on August 27, 2026

Medically reviewed · August 27, 2026

Compounded semaglutide legal status

The semaglutide shortage, its resolution in February 2025, the enforcement discretion dates, the salt-form issue, and the bases on which providers still compound it.

Regulatory facts on this page were checked at the medical review dated above and are re-checked at each review.

Shortage and resolution

Semaglutide injection entered FDA’s shortage list in 2022. Compounded semaglutide, sold through telehealth at prices well below the approved products, became the largest category of compounded GLP-1 during the shortage. On 21 February 2025 FDA declared the semaglutide shortage resolved. Enforcement discretion for compounders followed the tirzepatide pattern: 503A pharmacies until 22 April 2025 and 503B outsourcing facilities until 22 May 2025, after which FDA said it would apply its ordinary enforcement approach to copies of the approved semaglutide products.

The salt-form issue

FDA has said that some compounders used semaglutide sodium or semaglutide acetate, salt forms that differ from the base semaglutide in the approved products and do not meet the conditions for compounding an active ingredient. This is distinct from the shortage question and applies whatever the shortage status. It is the reason this site records, for every compounded semaglutide plan, whether the provider or pharmacy states the form of the active ingredient.

Bases for continued compounding

As with tirzepatide, providers that continued after the enforcement dates generally cite a prescriber-determined change for the individual patient (strength, increment, added ingredient) or a presentation not commercially available. Whether a provider’s practice meets those conditions is for regulators and courts. The provider profile quotes what each provider says about its basis, when it says anything.

Oral semaglutide

Approved oral semaglutide products (Rybelsus, and the oral form of Wegovy) are manufacturer products with their own pricing. Compounded “oral”, sublingual or orally disintegrating semaglutide is a different matter: no published human trials of those compounded forms have been located by our review, and they carry evidence grade D on this site. The formulation evidence grades explain the scale.

What this means for a patient

The same two practical points as for tirzepatide: prepaid plans carry availability risk if enforcement changes, and a provider that names the pharmacy and the form of the active ingredient has answered the questions that matter most. The verification guide shows how to check a pharmacy’s licence and inspection history.

Questions this page answers

What is the problem with semaglutide sodium or semaglutide acetate?: FDA has stated that these salt forms are not the same active ingredient as the semaglutide in the approved products and has raised concerns about compounders using them. A provider that names its pharmacy and confirms the base form answers this question; one that does not is recorded as not disclosing the formulation.

Sources

Educational information, not medical advice. Decisions about GLP-1 medication belong with you and a licensed clinician who knows your history. Compounded medications are not FDA-approved. Report an error.